Eli Lilly and Company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Mounjaro (tirzepatide) injection a single molecule that activates the body's receptors for GIP and GLP-1 for people living with type 2 diabetes to assist individuals in obtaining the prescription drugs they are prescribed, and it will collaborate with physicians, insurers, and health systems to facilitate patient access to Mounjaro.
Stevanato Group together with Owen Mumford to expedite the Aidaptus auto-injector's manufacturing process and also provide pharmaceutical clients with pre-filled syringes so they may administer the finished product to patients.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3511
Published Date: Nov 14, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising cases of rheumatoid arthritis and the growing government initiatives to increase awareness are the major factors driving the growth of the market.
The market size of Auto-injectors is anticipated to attain a CAGR of 17% over the forecast period, i.e., 2024-2036.
The major players in the market are Scandinavian Health Ltd., AbbVie, Inc., Amgen, Owen Mumford, Ypsomed, Biogen Idec, Mylan N.V., Pfizer, Inc., Sanofi, and Stevanato Group.
The anaphylaxis segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.